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Abstract. Clinical diagnosis of Alzheimer’s disease (AD) relying on symptomatic features has a low specificity, emphasizing the
importance of the pragmatic use of neurochemical biomarkers. The most advanced and reliable markers are amyloid- (A42),
total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) with relatively high levels of sensitivity, specificity,
and diagnostic accuracy. Recent advances within the field of proteomics offer the potential to search for novel biomarkers in
CSF by using modern methods, such as microarrays. The purpose of this study was to identify pathognostic proteins in CSF
obtained from patients whose clinical AD diagnosis was confirmed by the “core” biomarkers. CSF samples were obtained from
25 AD patients and 25 control individuals. The levels of A42, t-tau, and p-tau were measured by ELISA. In the microarray
experiments, ultrasensitive slides representing of 653 antigens were used. Apolipoprotein E genotyping was also determined. A
decrease of seven CSF proteins in AD were found, four of them (POLG, MGMT, parkin, and ApoD) have a protective function
against neuronal death, while the remaining three proteins (PAR-4, granzyme B, Cdk5) trigger multiple pathways facilitating
neuronal cell death. Since these proteins from CSF samples could not be identified by western blot, their decreased levels in AD
patients were not verified. Our results provide new information of pathognostic importance of POLG and granzyme B in AD.
Although the function of MGMT, parkin, ApoD, PAR-4, and Cdk5 was previously known in AD, the findings presented here
provide novel evidence of the significance of CSF analysis in the mapping of the AD pathomechanism.
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INTRODUCTION26
Alzheimer’s disease (AD) is a neurodegenera-27
tive disorder characterized by the accumulation of28
amyloid- (A) and hyperphosphorylated tau (p-tau)29
protein with consequential neuronal loss, neuroin-30
flammation [1], and mitochondrial impairment [2, 3].31
The clinical diagnosis of AD during life is difficult,32
although neurochemical markers are gaining greater33
importance in clinical routine. Biomarkers may be
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useful not only in establishing the precise diagnosis 34
or differentiating AD from other dementias, but in 35
predicting the prognosis, as well [4]. Relating to the 36
amyloid-cascade and the tau hypotheses [5], the mea- 37
surements of A42, total tau (t-tau), and p-tau from 38
the cerebrospinal fluid (CSF) by ELISA are the most 39
commonly used diagnostic methods. The sensitivity of 40
these measurements is about 85%, while their speci- 41
ficity is even higher, about 95% [6]. However their 42
positive predictive value is much lower, especially in 43
prodromal AD, which has increasing diagnostic impor- 44
tance due to the advantages of early interventions. 45
Although ELISA procedures are well adapted and have 46
been optimized to measure samples in normal and 47
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pathological range [7], 34% of non-AD type demented48
patients have an AD biomarker profile and 36% of cog-49
nitively normal subjects have a pathological AD CSF50
profile [8].51
Currently, there is no other neurochemical diagnos-52
tic method which could detect changes of specific53
molecules related to the pathomechanism of AD,54
such as neuronal degeneration, neuroinflammation,55
oxidative stress, or mitochondrial impairment [9].56
Additionally, up to now, there are no data obtained57
from those AD patients who were diagnosed by58
not only the clinical routine National Institute59
of Neurological and Communicative Disorders and60
Stroke/Alzheimer’s Disease and Related Disorders61
Association (NINCDS/ADRDA) criteria [10, 11], but62
also by using approved CSF biomarkers.63
Therefore the aim of our study was to identify64
changes of proteins related to AD pathomechanism in65
CSF obtained from patients whose clinical AD diag-66
nosis was confirmed by A42, t-tau, and p-tau ELISA.67
In addition, the relationship between apolipoprotein68
E (ApoE) genotype and proteomic changes was also69
examined.70
MATERIALS AND METHODS71
Subjects72
The AD group consisted of 25 patients (9 men and73
16 women), the average age and standard deviation74
(SD) was 72.04 ± 5.03 years. The clinical diagnosis of75
AD was validated by initial evaluation through careful76
history taking (personal and family histories), neuro-77
logical and psychiatric examinations, together with the78
assessment of psychometric tests to confirm cognitive79
impairment. Furthermore, a brain CT scan or MRI was80
conducted in each case, and in some cases SPECT was81
done to exclude other neurological diseases. Routine82
laboratory work-up including determination of thyroid83
hormone levels was also carried out. All participants84
fulfilled criteria outlined in the Fourth edition of the85
Diagnostic and Statistical Manual of Mental Disorders86
(DSM-IV, 1994) [12] and had probable AD according87
to the criteria of NINCDS–ADRDA [10, 11].88
The cognitive evaluation of AD patients was carried89
out using the AD Assessment Scale – Cognitive Sub-90
scale [13, 14], the Mini-Mental State Exam (MMSE)91
[15, 16], and the Clock Drawing Test [17]. Mood was92
scored using Beck Depression Inventory [18]. The93
average score and SD of MMSE of AD patients was94
15.16 ± 2.55.95
Control subjects without any subjective symptoms 96
of cognitive dysfunction were recruited from the Neu- 97
rology Department of our University. A thorough 98
neurological examination, routine lab tests, and brain 99
CT or MRI were also conducted on the control par- 100
ticipants. The control group consisted of 25 age- 101
and gender-matched (9 men, 16 women) individuals. 102
The average age and SD of the control group was 103
74.52 ± 2.48 years. 104
Ethical permission for lumbar puncture was 105
obtained from the Ethics Committee of the University 106
of Szeged, Hungary, where written informed con- 107
sent had been required for all probands (permit No. 108
184/2012). 109
CSF collection 110
CSF samples used in this study were obtained from 111
patients undergoing a lumbar puncture in the L4–L5 112
vertebral interspace. All the interventions were per- 113
formed in the morning, between 9.00 a.m. - 11.00 a.m. 114
Twelve ml of CSF were collected into polypropylene 115
tubes from each patient and control individual. CSF 116
samples were transferred to the laboratory on −20◦C 117
within 1–2 hours. Each CSF sample was aliquoted and 118
frozen immediately to minimize any metabolic dam- 119
age. Routine laboratory investigation, such as protein 120
amount and cell count were determined, the remainder 121
of samples were stored at −80◦C until further analysis. 122
All measurements were done within 1–3 month after 123
sample collection. 124
Aβ42 and tau enzyme-linked immunosorbent assay 125
CSF samples were analyzed using ELISA 126
(GenoID®, INNOTEST hTAU, INNOTEST - 127
Amyloid, INNOTEST Phospho-Tau) according to the 128
manufacturer’s instructions. Internationally accepted 129
AD specific cutoff points were used. AD specific 130
values are A42 < 500 pg/mL, t-tau>600 pg/mL, 131
and p-tau>60 pg/mL. The normal (non-AD specific) 132
values (mean ± SD) are A42 794 ± 20 pg/mL, t-tau 133
341 ± 171 pg/mL, and p-tau 23 ± 2 pg/mL [6]. 134
ApoE polymerase chain reaction and restriction 135
fragment length polymorphism 136
ApoE genotypes were determined with a previously 137
described method [19]. Genomic DNA was extracted 138
from peripheral blood leukocytes using a kit (Roche 139
Applied Bioscience LTD), according to the manufac- 140
turer’s instructions. Polymerase chain reaction (PCR) 141
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and restriction fragment length polymorphism (RFLP)142
were used to analyze ApoE alleles.143
Peptide microarray analysis144
Master Antibody Microarray (Spring BioScience®,145
Cat. # AMS-700) was used to perform antibody array146
studies, according to the manufacturer’s instructions.147
The specific antibodies were covalently immobilized148
on glass surface coated with 3D polymer materials to149
ensure high binding efficiency and specificity. Each150
slide was printed with 656 unique antibodies, positive151
and negative controls in duplicate. Two replicates were152
used to minimize errors on each microarrays.153
Pooled samples of 5 AD patients or 5 control patients154
were analyzed on the 5 antibody arrays. The con-155
centration of native CSF proteins was measured with156
bicinchoninic acid before pooling them to determine157
the concentrations of the single samples. First, 2.7 mg158
of proteins of pooled CSF were precipitated overnight159
with acetone (4:1; acetone:CSF) at −20◦C and then160
centrifuged at 14000 × g for 15 min at 4◦C. To remove161
salts, the supernatant was discharged and the pel-162
let was resuspended in 500l −20◦C 90% acetone.163
It was centrifuged at 14000 × g for 5 min at 4◦C.164
The resulted protein pellet was resuspended in 50l165
labelling buffer of the Antibody Microarray Detection166
Kit (Spring BioScience®, Cat. #AMD-001). The con-167
centration of resuspended samples was measured with168
NanoDrop-2000. Protein samples were then biotiny-169
lated and conjugated to the antibody array. To visualize170
the coupled proteins Cy3-Streptavidin was used (GE171
Healthcare, Cat. # PA43001). Fluorescent staining of172
653 proteins on peptide microarrays was measured173
using an Agilent scanner. Image analysis and normal-174
ization were done by the Genepix Pro 6.0 software.175
Each spot was defined by automatic positioning of176
a grid given by the manufacturer. The median values177
of feature and local background pixel intensities were178
determined. Background corrected intensity data were179
filtered for flagged spots and weak signals. Techni-180
cal replicates on the same array were averaged. Data181
were excluded in cases where technical replicates were182
significantly different or only one of the replicate had183
shown change in intensity. Median normalization was184
performed. Ratio of AD values and control values was185
used to determine alterations. A ratio below 0.6 meant186
a decrease, while a ratio above 1.8 meant increase of187
the given protein level.188
Western blot analysis189
To confirm our previous results, 20g or 40g190
of protein was used and separated on 12% SDS-191
polyacrylamide gel and electroblotted (100V/ 45 min) 192
onto PVDF or nitrocellulose membranes. The sam- 193
ples were blocked in a solution of 0.2 M Tris-buffered 194
saline containing 0.02% Tween 20 (TBST) supple- 195
mented with 5% non-fat milk for 1 h. The membranes 196
were then incubated overnight with rabbit polyclonal 197
MGMT, PAR-4, and granzyme B (Bioss INC.; cat# 198
bs-1196R; bs-1351R; bs-1002R) All of them was 199
tested at different dilutions, as follows 1:500; 1:1000; 200
1:2000. The next day, after five washes with TBST, 201
horseradish-peroxidase-labelled anti-rabbit IgG (Jack- 202
son Immunoresearch, West Grove, PA, USA; 1:1000) 203
secondary antibody was applied for 90 min. The mem- 204
branes were subsequently washed five times with 205
TBST, and incubated with the Supersignal® West Pico 206
Chemiluminescent Substrate (Pierce, Rockford, IL, 207
USA) and exposed to KODAK autography film. 208
Statistical analysis 209
Statistical analyses were performed by IBM SPSS 210
statistics 20 software. Student’s t-test was used due 211
to the normal distribution of the values. The level of 212
significance was ∗∗∗p≤ 0.001. 213
RESULTS 214
To confirm the clinical diagnoses of AD, the levels 215
of A42, t-tau, and p-tau proteins of the CSF samples 216
were measured using ELISA. A42, t-tau, and p-tau 217
levels of control probands (n = 25) were in interna- 218
tionally accepted normal range (A42 666.0 ± 270.1 219
pg/mL; t-tau 270.1 ± 83.9 pg/mL; p-tau 60.2 ± 17.5 220
pg/mL). We observed significant decrease in A42 221
levels (p = 0.000117), and significant increase in t-tau 222
(p = 0.000008), and p-tau (p = 0.000544) levels in the 223
AD group compared with control probands (Fig. 1). 224
Based on the PCR fragment analysis, 9 of the 25 225
AD patients were heterozygous for ApoE4 and ApoE3 226
alleles (Table 1). Only 1 patient was heterozygous for 227
ApoE2 and ApoE4 allele (Table 1). The remaining 15 228
patients were homozygous for ApoE3 allele (Table 1). 229
Comparing the AD and control samples based on 230
complex analysis of pixel intensity, we found reduc- 231
tion in the cases of 7 proteins in 4 of the 5 pairs. Fig. 2 232
demonstrates representative original array scans from 233
two AD pooled CSF samples with their matched con- 234
trol ones. The proteins with decreased levels in AD 235
CSF were the following: DNA polymerase gamma 236
(POLG) (Table 2; Fig. 3), methylated-DNA-protein- 237
cysteine methyltransferase (MGMT) (Table 2; Fig. 3), 238
parkin (Table 2; Fig. 3), apolipoprotein D (ApoD) 239
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Fig. 1. A42, t-tau, and p-tau levels in CSF of AD patients and con-
trol probands were measured by Innogenetics and Invitrogen ELISA
kits. The columns mean the averages of A42, t-tau, and p-tau levels,
the bars indicate the standard deviation (∗∗∗p≤ 0.001).
Table 1
Distribution of ApoE alleles in 25 AD patients involved in the study
2/2 2/3 2/4 3/3 3/4 4/4
ApoE alleles 0 0 1 15 9 0
(Table 2; Fig. 3), protein kinase C apoptosis WT1 reg-240
ulator protein (PAR-4) (Table 2; Fig 3), granzyme B241
(Table 2; Fig. 3), and cyclin-dependent kinase 5 (Cdk5)242
(Table 2; Fig. 3).243
Western blot might be a proper verification method244
to confirm the decrease of proteins expression found245
in CSF, shown by microarray. Although different set-246
tings were tested, we cannot confirm our results by247
western blot, because there were no signals on 23 kDa248
(MGMT), 37 kDa (PAR-4), and 27.7 kDa (granzyme249
B). The representative pictures of the blots are shown250
in Fig. 3.251
DISCUSSION252
This study revealed two totally novel proteins in253
CSF of patients affected with AD, namely POLG and254
granzyme B. In addition, we are the first to describe255
the decrease of five proteins, such as MGMT, parkin,256
ApoD, PAR-4, and Cdk5 related to the neuronal cell257
death in CSF of AD patients, despite the fact that the258
central factor of neuronal degeneration in the path-259
omechanism of AD has been known for a long time260
[2, 20, 21]. It is important to emphasize that the pro-261
teomic microarray analyses were performed on CSF262
from patients with clinically verified AD diagnosis by263
using AD specific neurochemical CSF markers.264
One of the seven proteins found in decreased level 265
in CSF samples of AD patients is POLG—critical for 266
the synthesis, replication, and repair of mitochondrial 267
DNA (mtDNA)—which has not been studied in either 268
CSF or in brain tissue of patients with AD (Table 2). 269
Our study was the first to recognize the reduced levels 270
of POLG in CSF samples from AD patients. The rela- 271
tionship between POLG and the pathomechanism of 272
AD has been suggested based on a detailed morpho- 273
logical mtDNA and genetic study of the brains of two 274
siblings with progressive cognitive decline, AD pathol- 275
ogy, POLG mutation, and ApoE4/4 genotype [22]. Our 276
results are consistent with the findings of Podlesniy et 277
al. [23], who found reduced mtDNA in CSF of patients 278
with sporadic AD. Since abnormal function of POLG 279
leads to cell death cascade via mitochondrial dysfunc- 280
tion and oxidative stress, these previous results and 281
our data led us to conclude that the decreased levels 282
of POLG in CSF from AD patients may reflect the 283
mitochondrial dysfunction characteristic of this dis- 284
ease (Fig. 4). 285
MGMT is a specific repair protein that removes the 286
alkyl group from an important site of DNA alkyla- 287
tion (Table 2; Fig. 4). So far only one study has been 288
performed to measure the activity of MGMT in lym- 289
phocyte preparations from AD patients and control 290
subjects which did not reveal any significant differ- 291
ences [24]. In contrast to these previous data, our 292
results are the first to show reduced levels of MGMT 293
in the CSF of AD patients. The apparent discrepancy 294
between the earlier findings and our results can be 295
explained by the difference in the used samples and 296
techniques. Since, in the case of AD, changes in CSF 297
are more relevant than those of the peripheral lym- 298
phocytes, a potential relation between the reduction of 299
MGMT and AD pathomechanism can be suggested. 300
Parkin so far has not been investigated in similar 301
human ex vivo CSF measurements (Table 2). Parkin is 302
an ubiquitin E3 ligase involved in proteasomal degra- 303
dation of misfolded proteins (Fig. 4) [25]. Parkin 304
ubiquitinates intracellular A in vivo and stimulates its 305
removal via the proteasome or the autophagy-lysosome 306
system [26]. Decreased parkin solubility was detected 307
in postmortem AD cortex [27]. Overexpression of 308
parkin in double or triple transgenic animal models of 309
AD restored activity-dependent synaptic plasticity, res- 310
cued behavioral abnormalities, down-regulated APP 311
expression, reversed the effects of AD genes on inflam- 312
mation and brain atrophy, suggesting that parkin could 313
be a promising target for AD therapy [28, 29]. Our 314
data provide further evidence of the role of parkin in 315
the pathomechanism of AD, and we suggest that its 316
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Fig. 2. Photographs of representative pseudo-colored images of protein microarrays from Alzheimer’s disease and control cerebrospinal fluid
samples. The software colored the spots in order to visualize the level of intensity. Blue means the weakest signal intensities, accordingly. On
each slide blocks are duplicated (Alzheimer’s disease 1A and 1B; control 1A and 1B, Alzheimer’s disease 2A and 2B; control 2A and 2B).
Table 2
Lists of proteins showing decreased level in CSF of AD patients
Name Ratio ± S.E.M. of AD and control Molecular Function of
optical intensities of CSF proteins weight (kDa) proteins
POLG 0.51 ± 0.19 139.6 • replication of mitochondrial DNA
• mitochondrial functions
MGMT 0.56 ± 0.11 21.6 • DNA protection
Parkin 0.59 ± 0.1 51.6 • protein catabolism
ApoD 0.62 ± 0.17 21.3 • transport processes
PAR-4 0.6 ± 0.08 36.6 • apoptosis
Granzyme B 0.37 ± 0.24 27.7 • apoptosis
CDK5 0.45 ± 0.09 33.3 • regulation of cell cycle
• apoptosis
The numbers represent the ratio of pixel intensities derived from 5 control and 5 Alzheimer’s disease independent microarrays.
One microarray sample was a pooled construction of 5 individual CSF samples derived from control or Alzheimer’s disease groups,
respectively. Molecular weight and function of the seven proteins are also presented. AD, Alzheimer’s disease; POLG, DNA polymerase
gamma; MGMT, methylated-DNA-protein-cysteine methyltransferase; ApoD, apolipoprotein D; PAR-4, protein kinase C apoptosis
WT1 regulator protein; Cdk5, cyclin-dependent kinase 5; S.E.M., standard error of mean; CSF, cerebrospinal fluid.
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Fig. 3. Representative blot images from Alzheimer’s disease and control cerebrospinal fluid samples. There were no signals on 23 kDa (MGMT),
on 37 kDa (PAR-4), and on 27.7 kDa (granzyme B). MGMT, methylated-DNA-protein-cysteine methyltransferase; PAR-4, protein kinase C
apoptosis WT1 regulator protein; 1C-4C, control samples; 1AD-4AD, Alzheimer’s disease samples
decreased level in the CSF may be the consequence317
of a compensatory intraneuronal parkin accumulation318
with A and p-tau.319
ApoD, a member of the lipocalin superfamily of320
lipid transport proteins, has been previously associ-321
ated with AD (Table 2). However, its exact role is322
unclear. Upregulation of ApoD expression has been323
detected in the hippocampus or frontal cortex [30–32],324
and increased ApoD concentrations were also demon-325
strated in the hippocampus and in CSF of AD patients326
[33]. In contrast to this data measured by immunoblot327
and radioimmunometric assay, the peptide microarray328
analysis in our experimental setting showed a reduc-329
tion of ApoD levels in the CSF of AD patients (Fig. 4).330
These various results can be explained with not only the331
different techniques used by the cited authors and us,332
but the different ApoE genotypes between the two AD333
populations. Terrisse et al. found correlation between334
the inheritance of ApoE4 allele and increased ApoD335
concentrations in a dose dependent manner in CSF of 336
AD patients [33]. ApoE genotyping of our AD patients 337
verified the presence of the ApoE4 allele in 10:50 ratio, 338
which is considerably lower than the 24:60 ApoE4 339
allele ratio in the study of Terrisse et al. [33]. The rela- 340
tively low number of ApoE4 allele in the investigated 341
AD population may also explain the lack of any cor- 342
relation between the found reduction of other proteins 343
in CSF and ApoE genotyping. 344
PAR-4, a mediator of neuronal degeneration asso- 345
ciated with AD (Table 2) [34, 35], has also not been 346
tested yet in CSF of AD patients. Earlier, the levels of 347
PAR-4 mRNA and protein were found to be increased 348
in tissue from vulnerable brain regions of AD patients 349
compared to age-matched control patients [34, 35]. The 350
present study reveals for the first time the decreased 351
levels of PAR-4 in CSF of AD patients. Theoretically, 352
PAR-4 may accumulate in AD brain causing a low 353
level in CSF similar to A, but its verification needs 354
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Fig. 4. Scheme how the proteins with reduced levels in AD CSF are involved in the pathomechanism of this disease. MGMT, parkin, POLG,
and ApoD may have protective roles against neuronal degeneration; this is shown by the light grey arrows. PAR-4, granzyme B, and Cdk5 have
roles in mediating neuronal cell death, which is presented by the dark grey arrows. POLG, DNA polymerase gamma; MGMT, methylated-DNA-
protein-cysteine methyltransferase; ApoD, apolipoprotein D; PAR-4, protein kinase C apoptosis WT1 regulator protein; Cdk5, cyclin-dependent
kinase 5; CSF, cerebrospinal fluid; AD, Alzheimer’s disease.
further experiments. With regards to the function of355
PAR-4 (Fig. 4), it was initially identified to be asso-356
ciated with aberrant A production due to its direct357
involvement in regulation of the -secretase (BACE1)358
activation [36]. Additionally, a novel mechanism of359
glial apoptosis induction by PAR-4-enriched exosomes360
was recently reported, which may critically contribute 361
to AD [37]. 362
PAR-4 is a substrate of caspase during apoptosis, 363
and this activation of caspases appears to be mediated 364
by granzyme B (Table 2; Fig. 4) [38, 39]. Interest- 365
ingly, not only the levels of PAR-4 but also those of 366
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granzyme B are decreased in CSF obtained from AD367
patients compared to the control group. Despite the368
fact that granzyme B is another important regulator of369
apoptosis [39, 40], and has been investigated in inflam-370
matory mediated neurodegenerative disorders [41], its371
potential role in AD has not been examined. The expla-372
nation of reduced granzyme B levels in CSF may be373
that granzyme B is able to enter into the target neurons374
inducing apoptosis of them [42], therefore its extracel-375
lular concentration may be reduced. The specificity of376
the reduced levels of granzyme B in CSF also requires377
further examinations.378
Another protein which decreased in CSF obtained379
from AD patients was Cdk5 (Table 2). This multi-380
functional enzyme triggers a cascade of pathways,381
contributing to all hallmarks of AD: neurotoxic A and382
neurofibrillary tangles formation, apoptosis, and neu-383
ronal death (Fig. 4) [43–46]. Normally, Cdk5 activity is384
tightly regulated in the nervous system by the neuron-385
specific, cyclin-related molecules p35 and p39. This386
regulation of Cdk5 is disrupted in AD, since high intra-387
cellular Ca++ activates calpain-mediated cleavage of388
p35 to p25, forming a more stable Cdk5/p25 complex,389
causing aberrant hyperphosphorylation of tau and neu-390
rofilament proteins, and inducing neuronal cell death391
[47]. Cdk5 also plays an important role in regulating392
the reorganization of the cytoskeleton [48]. Cdk5 mod-393
ulates the signaling of actin dynamics regulated by394
cofilin [49], the regulatory system possibly involved in395
stress-related biochemical events in AD [50]. The ear-396
lier postmortem data relating to brain levels of Cdk5 are397
contradictory. Recent studies show that Cdk5 protein398
levels in postmortem brains were significantly elevated399
in AD when compared to non-cognitively impaired400
controls, and that Cdk5 levels significantly correlated401
to BACE1 levels [51]. On the contrary, other publica-402
tions have reported that Cdk5 levels appear unchanged403
[43, 52]. These earlier reports and our own investiga-404
tion lead us to conclude that Cdk5 may play a crucial405
role in AD pathomechanism. However, its changes in406
opposite directions between the brain and CSF cannot407
be explained and require further investigation.408
We should emphasize that our results also have409
limitations. The microarray assay we used is highly410
sensitive [53] according to the references of the man-411
ufacturer of the kit, therefore it is able to detect even412
little alterations in the protein concentrations which are413
undetectable in high amounts of proteins with other414
widespread molecular methods, such as western blot415
[54, 55]. Similarly to our results, the attempts for416
validation of antibody microarray results were unsuc-417
cessful by either ELISA or western blot [54, 55]. The418
failure of the validation can be explained by the differ- 419
ent amounts of the tested proteins in the microarray and 420
the western blot experiments. Regarding the protein 421
quantities, 2.7 mg total CSF protein was analyzed in 422
the peptide microarray experiment. On the other hand, 423
an almost 70 times smaller amount, only 40g total, of 424
CSF protein was loaded on the gels in the western blot 425
experiment due to the limitations of this method. One 426
potential solution for this problem could be to concen- 427
trate the CSF samples to get stronger signals on the 428
blots, but this approach may cause biased results due 429
to the disproportional precipitation and loss of certain 430
subfractions of proteins [56]. On the other hand, west- 431
ern blot analysis is a semi-quantitative method, and the 432
difference within band size and density should be inter- 433
preted carefully, because the linearity of the staining 434
may be incorrect especially in the case of low amount 435
of proteins (below 5g) [57]. The special proteome 436
of CSF is 70–80% of the immunoglobulin and albu- 437
min. Furthermore, these may bind other proteins. On 438
the other hand, CSF has a low protein concentration, 439
but high salt content, and until now the highest effi- 440
ciency of protein precipitation is about 70–75% [56, 441
59]. Another characteristic of CSF is the high intra- and 442
interpersonal proteome variability. In order to reduce 443
the effects of this phenomenon, pooled samples were 444
used in our experimental design [59]. These limitations 445
make CSF investigation one of the most challenging 446
fields of biomarker research in AD and other neurode- 447
generative disorders. 448
All subjects included in our control group are 449
patients with different diseases (such as headache, 450
epilepsy) with the possibility of having impact on CSF 451
proteomes. On the basis of ethical considerations, there 452
is no possibility to gain CSF without any diagnostic 453
reason to find age- and gender-matched healthy control 454
probands. There was also no possibility to determine 455
the ApoE genotypes of this control group. 456
In conclusion, we are the first to provide data by 457
protein microarray approach in CSF samples from 458
neurochemically verified AD patients. We found a 459
decrease of seven proteins (POLG, MGMT, parkin, 460
ApoD, PAR-4, granzyme B, Cdk5) in AD CSF com- 461
pared to CSF of non-demented control probands. 462
Among these seven proteins, the pathognostic impor- 463
tance of POLG and granzyme B has not been 464
previously tested in AD. The function of all of these 465
proteins is associated with the pathomechanism of neu- 466
ronal degeneration. Interestingly, the reduced levels in 467
CSF were identified not only in the case of those pro- 468
teins which play protective roles against the neuronal 469
degeneration (POLG, MGMT, parkin, and ApoD), but 470
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in the case of those proteins (PAR-4, granzyme B,471
and Cdk5) which trigger multiple pathways facilitating472
neuronal cell death. The possible cause of the reduction473
of these destructive proteins can be explained by their474
pathological accumulations within the brain, although475
further analysis is needed to clarify the exact mecha-476
nism.477
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